Table 3.

Safety data

	Camostat mesilate (N = 77)	Placebo (N = 76)	Total (N = 153)
Number of patients with
Any adverse events	25 (32.5)	31 (40.8)	56 (36.6)
Any serious adverse events	1 (1.3)	0	1 (0.7)
Any adverse events that led to discontinuation of treatment	2 (2.6)	0	2 (1.3)
Any adverse drug reactions	9 (11.7)	7 (9.2)	16 (10.5)
Serious adverse drug reactions	0	0	0
Adverse drug reactions that led to discontinuation of treatment	2 (2.6)	0	2 (1.3)
Adverse events or adverse drug reactions resulting in death	0	0	0
Adverse drug reactions by system organ class/preferred term
Gastrointestinal disorders	4 (5.2)	5 (6.6)	9 (5.9)
Abdominal discomfort	1 (1.3)	1 (1.3)	2 (1.3)
Constipation	1 (1.3)	0	1 (0.7)
Diarrhea	2 (2.6)	1 (1.3)	3 (2.0)
Nausea	0	1 (1.3)	1 (0.7)
Stomatitis	0	1 (1.3)	1 (0.7)
Vomiting	0	1 (1.3)	1 (0.7)
Hepatobiliary disorders	1 (1.3)	1 (1.3)	2 (1.3)
Hepatic function abnormal	1 (1.3)	1 (1.3)	2 (1.3)
Laboratory tests	3 (3.9)	2 (2.6)	5 (3.3)
Alanine aminotransferase increased	1 (1.3)	2 (2.6)	3 (2.0)
Aspartate aminotransferase increased	0	1 (1.3)	1 (0.7)
Blood potassium increased	2 (2.6)	0	2 (1.3)
Blood alkaline phosphatase increased	0	1 (1.3)	1 (0.7)
Skin and subcutaneous tissue disorders	1 (1.3)	1 (1.3)	2 (1.3)
Drug eruption	1 (1.3)	0	1 (0.7)
Rash papular	0	1 (1.3)	1 (0.7)

Values are n (%)